PW Medtech Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

PW Medtech Group hat ein Gesamteigenkapital von CN¥4.8B und eine Gesamtverschuldung von CN¥0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥5.2B bzw. CN¥327.1M. PW Medtech Group Das EBIT des Unternehmens beträgt CN¥191.8M, so dass der Zinsdeckungsgrad -4.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥1.6B.

Wichtige Informationen

0.06%

Verhältnis von Schulden zu Eigenkapital

CN¥2.80m

Verschuldung

Zinsdeckungsgrad	-3.9x
Bargeld	CN¥1.74b
Eigenkapital	CN¥4.84b
Gesamtverbindlichkeiten	CN¥405.69m
Gesamtvermögen	CN¥5.25b

Jüngste Berichte zur Finanzlage

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Nov 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Recent updates

PW Medtech Group's (HKG:1358) Solid Earnings Are Supported By Other Strong Factors

Sep 26

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

Feb 18

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

Jan 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

Dec 10

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Nov 22

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1358Die kurzfristigen Aktiva des Unternehmens (CN¥2.0B) übersteigen seine kurzfristigen Passiva (CN¥149.3M).

Langfristige Verbindlichkeiten: 1358Die kurzfristigen Vermögenswerte des Unternehmens (CN¥2.0B) übersteigen seine langfristigen Verbindlichkeiten (CN¥177.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1358 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 1358 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 12.7% auf 0.06% zurückgegangen.

Schuldendeckung: 1358Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (7536.8%).

Zinsdeckung: 1358 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

PW Medtech Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Recent updates

PW Medtech Group's (HKG:1358) Solid Earnings Are Supported By Other Strong Factors

Insufficient new directors

PW Medtech Group Limited to Report First Half, 2024 Results on Aug 30, 2024

Now 21% overvalued after recent price rise

Upcoming dividend of HK$0.05 per share

Executive Chairman & CEO recently sold HK$53k worth of stock

Here's Why PW Medtech Group Limited's (HKG:1358) CEO Might See A Pay Rise Soon

PW Medtech Group Limited (SEHK:1358) announces an Equity Buyback for HKD 150 million worth of its shares.

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Upcoming dividend of HK$0.049 per share at 11% yield

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director Xingdong Zhang has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

New 90-day low: HK$0.52

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

New 90-day high: HK$2.31

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

New 90-day high: HK$2.29

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Market bids up stock over the past week

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

New 90-day high: HK$1.76

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen